Summary
Thermo Fisher Scientific Inc. announced on March 3, 2020, that it has entered into a Business Combination Agreement to acquire QIAGEN N.V. The acquisition will be executed through a wholly-owned subsidiary of Thermo Fisher commencing a public tender offer to purchase all issued ordinary shares of QIAGEN. This strategic move represents a significant growth initiative for Thermo Fisher, aiming to expand its offerings and market presence. Investors should note that this is a proposed transaction, and its completion is subject to various conditions, including regulatory approvals and the successful outcome of the tender offer. The company has provided supplemental information regarding this transaction via an investor presentation, and further details will be disclosed in subsequent filings and official offer documents.
Key Highlights
- 1Thermo Fisher Scientific is launching a tender offer to acquire QIAGEN N.V.
- 2The transaction is structured as a business combination through a wholly-owned acquisition subsidiary.
- 3A joint press release announcing the Business Combination Agreement was issued on March 3, 2020.
- 4Thermo Fisher has also provided supplemental investor information via a presentation.
- 5The completion of the acquisition is contingent upon customary closing conditions, including regulatory approvals.
- 6Investors are advised to review official tender offer materials for detailed terms and conditions.
- 7The filing includes a broad list of risks and uncertainties associated with the transaction.